Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients

Journal of Infectious Diseases

Volumn 189, Issue 5, 2004, Pages 837-846

  Miller, Michael D ^a   Margot, Nicolas ^a   Lu, Biao ^a   Zhong, Lijie ^a   Chen, Shan Shan ^a   Cheng, Andrew ^a   Wulfsohn, Michael ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VIRUS MUTATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MULTIVARIATE ANALYSIS; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; PHOSPHONIC ACIDS; PLACEBOS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RNA, VIRAL; THYMIDINE;

EID: 1542327561     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381784     Document Type: Article

References (37)

1. Sarafianos SG, Das KD, Clark AD Jr, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc Natl Acad Sci USA 1999; 96:10027-32.
2. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95:13471-6.
3. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44:3465-72.
4. Eloor S, Kemp SD, Hertogs K, Alcorn T, Larder BA. Patterns of HIV drug resistance in routine clinical practice: a survey of almost 12,000 samples from the USA in 1999 [abstract 169]. Antivir Ther 2000; 5: 132.
5. Lanier ER, Scott J, Ait-Khaled M, et al. Prevalence of mutations associated with resistance to antiretroviral therapy from 1999-2002 [poster 635]. In: Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Arlington, VA: Foundation for Retrovirology and Human Health, 2003:285.
6. Richman DD. Drug resistance and its implications in the management of HIV infection. Antivir Ther 1997; 2:41-58.
7. Skowron G, Whitcomb J, Wesley M, et al. Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V [abstract 81]. Antivir Ther 1999; 4:55-6.
8. Whitcomb JM, Paxinos EE, Huang W, et al. The presence of nucleoside analogue mutations (NAMS) is highly correlated with reduced susceptibility to all NRTIs [poster 569T]. In: Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Arlington, VA: Foundation for Retrovirology and Human Health, 2002:264.
9. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997; 41:1094-8.
10. Opravil M, Yerly S, Staszewski S, Stone C, Ait-Khaled M, Perrin L. Prior treatment with mono or dual NRTIs before HAART as predictor of virological failure in simplified abacavir-based triple NRTI regimens: results from the Simplified Maintenance Trial (SMT) and CNA30017 [abstract 120]. Antivir Ther 2000; 5:95.
11. Lanier ER, Hellmann N, Scott J, et al. Determination of a clinically relevant phenotypic resistance "cutoff" for abacavir using the PhenoSense assay [poster 254]. In: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Arlington, VA: Foundation for Retrovirology and Human Health, 2001:117.
12. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir Chem Chemother 1997; 8:1-23.
13. Arimilli M, Kim C, Bischofberger N. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 1997; 8: 557-64.
14. Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9(2- phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998; 42:1568-73.
15. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
16. Srinivas RV, Fridland A. Antiviral activities of 9-R-2- phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998; 42:1484-7.
17. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179:92-100.
18. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples [abstract 2115]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
19. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3-dideoxycytidine and 2′,3′-dideoxy- 3′-thiacytidine. Antimicrob Agents Chemother 1994; 38:275-81.
20. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997; 176:899-903.
21. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003; 77:5685-93.
22. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-63.
23. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17:1151-6.
24. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-9.
25. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16:1227-35.
26. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fuma-rate in nucleoside-resistant HIV-1 infection. Ann Intern Med 2003; 139:313-21.
27. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
28. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
29. White KL, Margot NA, Whin T, Petropoulos CJ, Naeger LK, Miller MD. Enzymatic analyses and replication capacity of HIV-1 reverse transcriptase mutants K65R and K65R+M184V [poster 3033]. In: Programs and abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002.
30. Yahi N, Tamalet C, Tourres C, Tivoli N, Fantini J. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy: incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci 2000; 7:507-13.
31. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-11.
32. McColl DJ, Margot NA, Cheng AK, Miller MD. Development of K65R versus thymidine analogue-associated mutations (TAMs) in antiretroviral-treated patients [poster 206]. In: Programs and abstracts of the 6th International Congress on Drug Therapy in HIV Infection (Glasgow). Tytherton, UK: Gardiner-Caldwell Group, 2002:78.
33. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-9.
34. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-46.
35. Miller MD, Margot NA, McColl DJ, Tran S, Coakley DF, Cheng AK. Genotypic and phenotypic characterization of virologic failure through 48 weeks among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz [poster 205]. In: Programs and abstracts of the 6th International Congress on Drug Therapy in HIV Infection (Glasgow). Tytherton, UK: Gardiner-Caldwell Group, 2002:77.
36. Margot NA, Johnson A, Cheng A, Coakley DF, Miller MD. Final 48-week genotypic and phenotypic analyses of study 907: tenofovir DF (TDF) added to stable background regimens [poster 414W]. In: Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Arlington, VA: Foundation for Retrovirology and Human Health, 2002:209.
37. Masquelier B, Tamalet C, Descamps D, et al. Identification of genotypic determinants of the virological response to tenofovir-including regimens in nucleoside reverse transcriptase inhibitor-experienced patients [abstract 126]. Antivir Ther 2002; 7:S105.